Kiora Pharmaceuticals, Inc. (KPRX) is a Biotechnology company in the Healthcare sector, currently trading at $2.44. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 2 out of 7 criteria passed.
Valuation: KPRX trades at a trailing Price-to-Earnings (P/E) of -1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.02.
Net income is $11M (loss), growing at -88.3%/yr. Net profit margin is 0% (thin). Gross margin is 99.9% (+0 pp trend).
Balance sheet: total debt is $368,259 against $16M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 5.99 (strong liquidity). Debt-to-assets is 1.5%. Total assets: $24M.
Analyst outlook: 3 / 3 analysts rate KPRX as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).
